{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:41:49Z","timestamp":1784119309841,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":869,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical Foundation Queen Elisabeth"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s13311-021-01007-8","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T05:05:34Z","timestamp":1613711134000},"page":"949-961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["LRRK2 Ablation Attenuates Alpha-Synuclein\u2013Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo"],"prefix":"10.1016","volume":"18","author":[{"given":"Anke","family":"Van der Perren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cabezudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Gelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier M.","family":"Peralta Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Van den Haute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Baekelandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6417-4670","authenticated-orcid":false,"given":"Evy","family":"Lobbestael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01007-8_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-49969-7_1","article-title":"Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease","volume":"14","author":"Monfrini","year":"2017","journal-title":"Adv Neurobiol."},{"issue":"46","key":"10.1007\/s13311-021-01007-8_bib2","doi-asserted-by":"crossref","first-page":"16842","DOI":"10.1073\/pnas.0507360102","article-title":"Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity","volume":"102","author":"West","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America."},{"issue":"2","key":"10.1007\/s13311-021-01007-8_bib3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nbd.2006.04.001","article-title":"Kinase activity is required for the toxic effects of mutant LRRK2\/dardarin","volume":"23","author":"Greggio","year":"2006","journal-title":"Neurobiol Dis."},{"key":"10.1007\/s13311-021-01007-8_bib4","doi-asserted-by":"crossref","unstructured":"Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson's disease. Sci Transl Med. 2018;10(451).","DOI":"10.1126\/scitranslmed.aar5429"},{"key":"10.1007\/s13311-021-01007-8_bib5","doi-asserted-by":"crossref","unstructured":"West AB. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Exp Neurol. 2017;298(Pt B):236-45.","DOI":"10.1016\/j.expneurol.2017.07.019"},{"issue":"3","key":"10.1007\/s13311-021-01007-8_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.115.227587","article-title":"MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition","volume":"355","author":"Fell","year":"2015","journal-title":"J Pharmacol Exp Ther."},{"issue":"8","key":"10.1007\/s13311-021-01007-8_bib7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/ml300123a","article-title":"Brain Penetrant LRRK2 Inhibitor","volume":"3","author":"Choi","year":"2012","journal-title":"ACS Med Chem Lett."},{"issue":"1","key":"10.1007\/s13311-021-01007-8_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1021\/jm5014055","article-title":"Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor","volume":"58","author":"Henderson","year":"2015","journal-title":"J Med Chem."},{"key":"10.1007\/s13311-021-01007-8_bib9","unstructured":"Denali. http:\/\/investors.denalitherapeutics.com\/news-releases\/news-release-details\/denali-therapeutics-announces-positive-clinical-results-lrrk2#ir-pages."},{"issue":"6","key":"10.1007\/s13311-021-01007-8_bib10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.neuron.2009.11.006","article-title":"Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein","volume":"64","author":"Lin","year":"2009","journal-title":"Neuron."},{"issue":"25","key":"10.1007\/s13311-021-01007-8_bib11","doi-asserted-by":"crossref","first-page":"9289","DOI":"10.1073\/pnas.1403215111","article-title":"Abrogation of alpha-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats","volume":"111","author":"Daher","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America."},{"issue":"32","key":"10.1007\/s13311-021-01007-8_bib12","doi-asserted-by":"crossref","first-page":"19433","DOI":"10.1074\/jbc.M115.660001","article-title":"Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates alpha-Synuclein Gene-induced Neurodegeneration","volume":"290","author":"Daher","year":"2015","journal-title":"J Biol Chem."},{"issue":"28","key":"10.1007\/s13311-021-01007-8_bib13","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1523\/JNEUROSCI.3642-15.2016","article-title":"G2019S-LRRK2 Expression Augments alpha-Synuclein Sequestration into Inclusions in Neurons","volume":"36","author":"Volpicelli-Daley","year":"2016","journal-title":"J Neurosci."},{"key":"10.1007\/s13311-021-01007-8_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nbd.2015.02.019","article-title":"Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease","volume":"77","author":"Tsika","year":"2015","journal-title":"Neurobiol Dis."},{"issue":"6","key":"10.1007\/s13311-021-01007-8_bib15","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00401-019-01995-0","article-title":"LRRK2 modifies alpha-syn pathology and spread in mouse models and human neurons","volume":"137","author":"Bieri","year":"2019","journal-title":"Acta Neuropathol."},{"issue":"11","key":"10.1007\/s13311-021-01007-8_bib16","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/hmg\/dds057","article-title":"Neurodegenerative phenotypes in an A53T alpha-synuclein transgenic mouse model are independent of LRRK2","volume":"21","author":"Daher","year":"2012","journal-title":"Hum Mol Genet."},{"key":"10.1007\/s13311-021-01007-8_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2018.04.011","article-title":"Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-alpha-synuclein is normalized by LRRK2 modulation","volume":"116","author":"Andersen","year":"2018","journal-title":"Neurobiol Dis."},{"issue":"1","key":"10.1007\/s13311-021-01007-8_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40478-019-0679-5","article-title":"LRRK2 inhibition does not impart protection from alpha-synuclein pathology and neuron death in non-transgenic mice","volume":"7","author":"Henderson","year":"2019","journal-title":"Acta Neuropathol Commun."},{"key":"10.1007\/s13311-021-01007-8_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 Antisense Oligonucleotides Ameliorate alpha-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol Ther Nucleic Acids."},{"issue":"1","key":"10.1007\/s13311-021-01007-8_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12868-016-0315-2","article-title":"Leucine-rich repeat kinase 2 (LRRK2) regulates alpha-synuclein clearance in microglia","volume":"17","author":"Maekawa","year":"2016","journal-title":"BMC Neurosci."},{"key":"10.1007\/s13311-021-01007-8_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nbd.2019.05.012","article-title":"Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with alpha-synuclein fibrils","volume":"129","author":"Russo","year":"2019","journal-title":"Neurobiol Dis."},{"key":"10.1007\/s13311-021-01007-8_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1326-8-44","article-title":"rAAV2\/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration","volume":"8","author":"Oliveras-Salva","year":"2013","journal-title":"Mol Neurodegener."},{"issue":"3","key":"10.1007\/s13311-021-01007-8_bib23","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.neurobiolaging.2014.11.015","article-title":"Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors","volume":"36","author":"Van der Perren","year":"2015","journal-title":"Neurobiol Aging."},{"issue":"5","key":"10.1007\/s13311-021-01007-8_bib24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/gt.2010.179","article-title":"Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2\/1, 2\/2, 2\/5, 2\/6.2, 2\/7, 2\/8 and 2\/9","volume":"18","author":"Van der Perren","year":"2011","journal-title":"Gene Ther."},{"issue":"7","key":"10.1007\/s13311-021-01007-8_bib25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1089\/10430340252899019","article-title":"Characterization of lentiviral vector-mediated gene transfer in adult mouse brain","volume":"13","author":"Baekelandt","year":"2002","journal-title":"Hum Gene Ther."},{"issue":"4","key":"10.1007\/s13311-021-01007-8_bib26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.neuroscience.2004.08.050","article-title":"Design-based stereology in neuroscience","volume":"130","author":"Schmitz","year":"2005","journal-title":"Neuroscience."},{"issue":"3","key":"10.1007\/s13311-021-01007-8_bib27","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.neurobiolaging.2015.01.014","article-title":"FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an alpha-synuclein-based rat model for Parkinson's disease","volume":"36","author":"Van der Perren","year":"2015","journal-title":"Neurobiol Aging."},{"issue":"3","key":"10.1007\/s13311-021-01007-8_bib28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/BJ20100784","article-title":"Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)\/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization","volume":"430","author":"Dzamko","year":"2010","journal-title":"Biochem J."},{"issue":"40","key":"10.1007\/s13311-021-01007-8_bib29","doi-asserted-by":"crossref","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"J Biol Chem."},{"issue":"1","key":"10.1007\/s13311-021-01007-8_bib30","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1038\/s41467-018-05958-z","article-title":"LRRK2 kinase regulates alpha-synuclein propagation via RAB35 phosphorylation","volume":"9","author":"Bae","year":"2018","journal-title":"Nat Commun."},{"issue":"8","key":"10.1007\/s13311-021-01007-8_bib31","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41593-019-0457-5","article-title":"Spread of alpha-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis","volume":"22","author":"Henderson","year":"2019","journal-title":"Nat Neurosci."},{"key":"10.1007\/s13311-021-01007-8_bib32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.nbd.2018.09.003","article-title":"Nigrostriatal pathology with reduced astrocytes in LRRK2 S910\/S935 phosphorylation deficient knockin mice","volume":"120","author":"Zhao","year":"2018","journal-title":"Neurobiol Dis."},{"issue":"1","key":"10.1007\/s13311-021-01007-8_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008784","article-title":"Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease","volume":"5","author":"Sanchez-Guajardo","year":"2010","journal-title":"PLoS One."},{"key":"10.1007\/s13311-021-01007-8_bib34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.expneurol.2017.11.010","article-title":"Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease","volume":"300","author":"Harms","year":"2018","journal-title":"Exp Neurol."},{"key":"10.1007\/s13311-021-01007-8_bib35","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fnins.2020.00376","article-title":"Multiple-hit hypothesis in Parkinson's disease: LRRK2 and inflammation","volume":"14","author":"Cabezudo","year":"2020","journal-title":"Frontiers in Neuroscience."},{"issue":"1","key":"10.1007\/s13311-021-01007-8_bib36","first-page":"182","article-title":"Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease","volume":"119","author":"Brochard","year":"2009","journal-title":"J Clin Invest."},{"issue":"7660","key":"10.1007\/s13311-021-01007-8_bib37","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature22815","article-title":"T cells from patients with Parkinson's disease recognize alpha-synuclein peptides","volume":"546","author":"Sulzer","year":"2017","journal-title":"Nature."},{"key":"10.1007\/s13311-021-01007-8_bib38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fimmu.2019.00080","article-title":"Peripheral Inflammation Regulates CNS Immune Surveillance Through the Recruitment of Inflammatory Monocytes Upon Systemic alpha-Synuclein Administration","volume":"10","author":"Peralta Ramos","year":"2019","journal-title":"Front Immunol."},{"issue":"4","key":"10.1007\/s13311-021-01007-8_bib39","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ana.25557","article-title":"Increased Immune Activation by Pathologic alpha-Synuclein in Parkinson's Disease","volume":"86","author":"Grozdanov","year":"2019","journal-title":"Ann Neurol."},{"issue":"5","key":"10.1007\/s13311-021-01007-8_bib40","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1523\/JNEUROSCI.5601-11.2012","article-title":"LRRK2 inhibition attenuates microglial inflammatory responses","volume":"32","author":"Moehle","year":"2012","journal-title":"J Neurosci."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01007-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01007-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301142X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301142X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01007-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:51:05Z","timestamp":1761807065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792301142X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S187874792301142X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01007-8","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LRRK2 Ablation Attenuates Alpha-Synuclein\u2013Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01007-8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}